KRAS and cancer: Introduction of an α-methyl group at Ser10 resulted in a molecule (MP-3995) with prolonged proteolytic stability and cellular blockade of pERK activity in KRASG12D (AsPC-1) cells but was inactive against a KRASWT cancer line (A375) harboring BRAFV600E, a MAPK pathway activating mutation that is downstream of KRAS.